Company press releases
Tid | Selskap | Tittel | Sektor | Kategori |
---|---|---|---|---|
15 Apr 2025 07:20 CEST |
NYKODE THERAPEUTICS ASA | Nykode announces that Michael Engsig, CEO; Agnete Fredriksen, CSO & Co-founder; and Harald Gurvin, CFO; have withdrawn their recent resignations and continue with Nykode; proposal of new Board members; potential dividend of NOK 1.00 per share | 20103010 Biotechnology | Inside information |
11 Apr 2025 18:59 CEST |
NYKODE THERAPEUTICS ASA | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
02 Apr 2025 09:40 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA - Notice of Extraordinary General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
27 Mar 2025 16:56 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory Notification of Trade by Closely Associated Party of a Primary Insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
27 Mar 2025 14:15 CET |
NYKODE THERAPEUTICS ASA | OSLO BØRS – TRADING RESUMPTION | 20103010 Biotechnology | Trading halts |
27 Mar 2025 13:33 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – resignation of Chair of the Board, Board Members, Chief Executive Officer, Chief Scientific Officer and Chief Financial Officer | 20103010 Biotechnology | Inside information |
27 Mar 2025 13:30 CET |
NYKODE THERAPEUTICS ASA | OSLO BØRS - TRADING SUSPENSION | 20103010 Biotechnology | Trading halts |
27 Feb 2025 20:30 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Preclinical Data Highlighting its Immune Tolerance Platform’s Ability to Modulate Multiple Key Immune Components in Autoimmune Disease | 20103010 Biotechnology | Non-regulatory press releases |
26 Feb 2025 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Quarterly report Q4 2024 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
14 Feb 2025 16:05 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – invitation to Q4 2024 financial results presentation | 20103010 Biotechnology | Non-regulatory press releases |
08 Jan 2025 10:50 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Publication of Phase 2 VB-C-02 Data Confirming Prolonged Benefit and Definitive Vaccination Effects | 20103010 Biotechnology | Non-regulatory press releases |
30 Dec 2024 19:47 CET |
NYKODE THERAPEUTICS ASA | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
30 Dec 2024 13:35 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Streamlining Board of Directors | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
20 Dec 2024 14:19 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory Notification of Trade | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
04 Dec 2024 19:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Presents New Data on Individualized Cancer Immunotherapy at the Personalized Cancer Vaccines Summit | 20103010 Biotechnology | Non-regulatory press releases |
27 Nov 2024 00:05 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Quarterly report Q3 2024 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
20 Nov 2024 18:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – invitation to Q3 2024 financial results presentation | 20103010 Biotechnology | Non-regulatory press releases |
08 Nov 2024 15:18 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA - Mandatory Notification of Trade by Closely Associated Party of a Primary Insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
08 Nov 2024 15:10 CET |
NYKODE THERAPEUTICS ASA | Disclosure of large shareholding in Nykode Therapeutics ASA | 20103010 Biotechnology | Major shareholding notifications |
08 Nov 2024 00:15 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – Webcast Invitation | 20103010 Biotechnology | Non-regulatory press releases |
07 Nov 2024 23:25 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics to Regain Control of VB10.NEO Program | 20103010 Biotechnology | Inside information |
06 Nov 2024 17:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at PEGS Europe | 20103010 Biotechnology | Non-regulatory press releases |
27 Sep 2024 08:11 CEST |
NYKODE THERAPEUTICS ASA | Major shareholding notification | 20103010 Biotechnology | Major shareholding notifications |
21 Aug 2024 16:20 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
21 Aug 2024 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Quarterly report Q2 2024 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
21 Aug 2024 06:30 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Strategic Repositioning of VB10.16 to Focus on Locally Advanced Cervical Cancer and Recurrent Metastatic Head and Neck Cancer | 20103010 Biotechnology | Inside information |
14 Aug 2024 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Issuance of Key Patent Covering Individualized Neoantigen Based Vaccines | 20103010 Biotechnology | Non-regulatory press releases |
01 Aug 2024 08:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – invitation to Q2 2024 financial results presentation | 20103010 Biotechnology | Non-regulatory press releases |
01 Jul 2024 20:20 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Grant of share options | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
20 Jun 2024 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting | 20103010 Biotechnology | Non-regulatory press releases |
11 Jun 2024 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy | 20103010 Biotechnology | Non-regulatory press releases |
24 May 2024 17:15 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Grant of share options | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
16 May 2024 11:46 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA - Minutes of Annual General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
14 May 2024 07:15 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer | 20103010 Biotechnology | Non-regulatory press releases |
14 May 2024 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Quarterly report Q1 2024 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
07 May 2024 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – invitation to Q1 2024 financial results presentation | 20103010 Biotechnology | Non-regulatory press releases |
25 Apr 2024 07:30 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA - Notice of Annual General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
19 Apr 2024 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer | 20103010 Biotechnology | Non-regulatory press releases |
19 Apr 2024 06:30 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Annual Report 2023 | 20103010 Biotechnology | Annual financial and audit Reports |
26 Mar 2024 15:30 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
21 Mar 2024 19:38 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
21 Mar 2024 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer | 20103010 Biotechnology | Non-regulatory press releases |
19 Mar 2024 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases | 20103010 Biotechnology | Non-regulatory press releases |
13 Mar 2024 14:57 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
08 Mar 2024 16:16 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
08 Mar 2024 13:31 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
04 Mar 2024 13:11 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
29 Feb 2024 16:27 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
28 Feb 2024 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Quarterly report Q4 2023 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
22 Feb 2024 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – invitation to Q4 2023 financial results presentation | 20103010 Biotechnology | Non-regulatory press releases |